Interventional Glaucoma

Comparisons of deep sclerectomy and trabeculectomy show the former to have better outcomes and fewer complications in cases where it is indicated.

The GMOPC was established in February 2020 at an inaugural meeting in Los Angeles, California, as an investigator-initiated clinical research study, with Heidelberg Engineering as an industry partner.

According to the company, the protocol enhancement for the RETeval Device marks an important step in mitigating vision loss from glaucoma.

Numerous studies have shown that adherence declines with more complex regimens of more than 1 or 2 bottles.

Physicians find that additional treatment is not required for many patients.

The pivotal trial of MINIject, STAR-V, now initiated in 13 sites across the US, has received positive feedback from glaucoma surgeons involved in the trial.

Robert J. Noecker, MD, MBA, discusses the IRIDEX consensus paper regarding MicroPulse transscleral therapy for glaucoma at AAO 2021.

Marking Glaucoma Awareness Month this month, Bausch + Lomb and the Glaucoma Research Foundation have released key findings from a survey of glaucoma patients that was designed to gain a greater understanding of the impact that hyperemia can have in the treatment and lives of people living with glaucoma.

The acquisition brings the Hydrus Microstent into Alcon’s global surgical portfolio. The company will leverage its global footprint and leadership in ophthalmology to drive future growth, bringing the device to more patients worldwide.

Robert J. Noecker, MD, MBA, discusses the IRIDEX consensus paper regarding MicroPulse transscleral therapy for glaucoma at AAO 2021.

At AAO, AbbVie presented results from the ARTEMIS study, showcasing IOP lowering that extends beyond the original 20-month timeframe.

At AAO, AbbVie presented results from the ARTEMIS study, showcasing IOP lowering that extends beyond the original 20-month timeframe.

The agreement includes Europe, Commonwealth of Independent States countries, China, India, parts of Latin America and the Oceania countries.

Mahmoud A. Khaimi, MD, developed a minimally invasive glaucoma surgery known as ab-interno canaloplasty as a treatment option between topical therapies and invasive surgery. The technique continues to prove its value.

Ahmad Aref, MD, and Paul Singh, MD, offer a recap of their EyeCon 2021 presentation.

The company’s IOPerfect combines artificial intelligence in a VR-like headset to allow tele-diagnosis and remote monitoring of glaucoma.

Benefits include better visualisation of ciliary processes and avoidance of tissue damage.

Polygenic risk score allows multiple variants to be tested simultaneously.

A gel stent allows for less invasive subconjunctival procedures and an easier recovery course than traditional forms of minimally invasive glaucoma surgery.

The 12-Month OMNI data from the prospective, multicenter GEMINI clinical trial show statistically significant postoperative reductions in mean IOP and suppression of daily IOP fluctuations.

PRS can modify disease outcomes due to other genes, such as MYOC.

Felipe Medeiros, MD, presents results from a phase 3 clinical extension study of the bimatoprost implant that found patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fiends.

Dr Felipe Medeiros in a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, noted that a phase 3 clinical extension study of the bimatoprost implant found that patients’ IOP was lowered and stayed low with no additional treatment or changes in their visual fields.

Alcon this week announced its plans to acquire glaucoma surgery device maker Ivantis Inc. in a $475 million deal.

Investigators find that mutations could lead to early treatment intervention.